Dr. Gogineni Comments on Oncology Drug Shortages

Keerthi Gogineni, MD
Published: Thursday, Jul 11, 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Of the 210 oncologists surveyed, 83% reported a shortage in a cancer drug that they wanted to use to treat their patients. Of those, 94% of oncologists said that their patients' treatment was affected.

Because of the drug shortages, oncologists were forced to make expensive drug substitutions. Despite the prevalence of drug shortage issues since 2006, Gogineni says, oncologists have received little guidance regarding what substitutions to make and ethical guidance about appropriate substitutions.
 
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Of the 210 oncologists surveyed, 83% reported a shortage in a cancer drug that they wanted to use to treat their patients. Of those, 94% of oncologists said that their patients' treatment was affected.

Because of the drug shortages, oncologists were forced to make expensive drug substitutions. Despite the prevalence of drug shortage issues since 2006, Gogineni says, oncologists have received little guidance regarding what substitutions to make and ethical guidance about appropriate substitutions.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x